根据在医学会议上公布的数据，在一项针对肥胖患者的研究中，再生元正在开发的一种实验性减肥药与诺和诺德的司美格鲁肽联合使用，与单独使用司美格鲁肽相比，肌肉量流失减少了50%。
An experimental weight-loss drug being developed by Regeneron used in combination with Novo Nordisk's semaglutide reduced the loss of muscle mass by 50% compared with the loss seen with semaglutide alone in a study of patients with obesity, according to data being presented at a medical meeting.